

Table 1. Patient Characteristics between AI (+) and AI (-) groups

	AI (+), n (%)	AI (-), n (%)
N	28	450
Gender (male)	19 (67.9)	340 (75.6)
Age (median)	69 (range: 47–90)	70 (range: 34–87)
PS		
0	13 (46.4)	210 (46.7)
1	11 (39.3)	194 (43.1)
2	4 (14.3)	31 (6.9)
3	0 (0.0)	14 (3.1)
4	0 (0.0)	1 (0.2)
Type of cancer		
Lung	15 (53.6)	151 (33.6)
Digestive tract	1 (3.6)	75 (16.7)
Head & Neck	2 (7.1)	63 (14.0)
Melanoma	1 (3.6)	44 (9.8)
Renal	0 (0.0)	41 (9.1)
Urothelial	3 (10.7)	31 (6.9)
Liver	2 (7.1)	29 (6.4)
Others	4 (14.3)	16 (3.6)
Type of ICI		
Anti-PD-1 Ab	18 (64.3)	363 (80.7)
Anti-PD-L1 Ab	9 (32.1)	70 (15.6)
Anti-CTLA4	0 (0.0)	2 (0.4)
Anti-PD-1& Anti-CTLA4 Ab	1 (3.6)	15 (3.3)
Combined agent		
None	20 (71.4)	341 (75.8)
Cytotoxic agents	6 (21.4)	68 (15.1)
Molecular target agents	2 (7.1)	41 (9.1)
Best overall response		
CR	2 (7.1)	23 (5.1)
PR	11 (39.3)	104 (23.1)
SD	8 (28.6)	127 (28.2)
Non-CR/non-PD	0 (0.0)	1 (0.2)
PD	4 (14.3)	141 (31.3)
NE	3 (10.7)	54 (12.0)
irAE occurrence		
(-)	12 (42.9)	293 (65.1)
(+)	16 (57.1)	157 (34.9)
G3≥irAE	6 (21.4)	66 (14.7)
ICI stop due to irAE	12 (75.0)*	92 (59.7)*
Death**	12 (42.9)	231 (51.3)

*% of irAE (+) cases, ** death observed until 2023/06/29